Literature DB >> 15215874

Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.

A V Novoselac, S Reddy, J Sanmugarajah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15215874     DOI： 10.1038/sj.leu.2403417

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

Review 1.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Authors:  Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

3.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

4.  Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.

Authors:  Guixia Ling; Tianhong Zhang; Peng Zhang; Jin Sun; Zhonggui He
Journal:  Int J Nanomedicine       Date:  2016-08-23

5.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.